News & Analysis on Clinical Trial Services & Contract Research And Development
Boehringer Ingelheim, Various
By Ben Hargreaves
- Last updated on
Boehringer Ingelheim rings the changes at the boardroom level, with three longstanding board members leaving, being replaced by internal appointments.
Allan Hillgrove, a member of the board of managing directors responsible for the Human Pharma and Biopharma business, will step down from his position and retire from the company. Hillgrove has been with Boehringer for 37 years, beginning initially as a sales representative before working his way up to his current role in 2013.
Replacing Hillgrove will be Carine Brouillon, who joined the company from Janssen in 2018. Brouillon is the current head of global therapeutic areas for the company and will step into the new role beginning January 1, 2020.
Joachim Hasenmaier will also retire at the end of this year, leaving his position on the board of managing directors and from his role as head of the Animal Health business. Similar to Hillgrove, he has spent a number of years at the company – by the time of his departure, he will have been with the company over 18 years.
Replacing Hasenmaier in the position will be Jean Scheftsik de Szolnok, who is the current managing director for Boehringer’s business in France.
The final retirement will be Andreas Neumann, who leaves the company at the end of this month. Neumann holds a position on the board of managing directors and is head of human resources. Rather than replace him, the company has decided instead to merge his responsibilities with that of the chairman of the board, Hubertus von Baumbach.